PI Post Acute Access Act
- Sponsor
- Rep. Smith, Adrian [R-NE-3]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Apr 27, 2026
Bottom line
This bill clarifies and expands Medicare coverage for essential IVIG treatments for primary immunodeficiency patients in skilled nursing facilities, potentially improving access and reducing financial burdens for a vulnerable population.
What it actually does
This bill, the "PI Post Acute Access Act," amends Title XVIII of the Social Security Act to explicitly include intravenous immune globulin (IVIG) treatments for primary immunodeficiency disease, along with related items and services, within the scope of Medicare's skilled nursing facility (SNF) benefit. By adding specific HCPCS codes to the relevant section of the Act, it aims to ensure consistent coverage for these specialized therapies when provided in a SNF setting, effective October 1, 2026.
Proponents argue
Supporters argue that this bill addresses a critical gap in Medicare coverage, ensuring that vulnerable primary immunodeficiency patients can receive their life-sustaining IVIG treatments in skilled nursing facilities without facing prohibitive costs or access barriers. They contend that current regulations may inadvertently exclude these necessary treatments, forcing patients into less appropriate or more expensive care settings, or delaying vital therapy. This amendment provides clarity and consistency, aligning Medicare policy with the medical needs of these patients.
Opponents contend
Critics might express concerns about the potential for increased Medicare expenditures, arguing that explicitly adding these services could lead to higher utilization rates or shift costs from other care settings to SNFs, without a clear mechanism for offsetting these new costs. They might also suggest that existing coverage mechanisms, if properly interpreted, should already cover medically necessary IVIG, and that this bill could set a precedent for itemizing specific treatments rather than relying on broader medical necessity criteria.
The bill is very short and clearly written, allowing for quick comprehension by any interested reader.
Section 2(a)
Inclusion of IVIG for Primary Immunodeficiency in SNF Coverage
This provision directly modifies Section 1888(e)(2)(A)(iii) of the Social Security Act, which governs Medicare payments for skilled nursing facility (SNF) services. It adds a new subclause to explicitly include intravenous immune globulin (IVIG) used to treat primary immune deficiency disease, along with all associated items and services. The bill specifies a list of HCPCS codes (J1561, J1569, J1576, J1568, J1459, J1554, J1557, J1566) to identify these treatments, ensuring they are covered when administered in a SNF. This change is slated to take effect for services furnished on or after October 1, 2026.
Supporters argue
Supporters argue that this explicit inclusion is vital for patients who rely on IVIG to manage their primary immunodeficiency, preventing complications and improving quality of life. They contend that without this clarity, patients might face denials or have to seek care in more expensive or less convenient settings, undermining the goal of comprehensive post-acute care.
Critics contend
Opponents, if any, might argue that this specific enumeration of codes could lead to administrative complexities or open the door for other specific treatments to demand similar legislative carve-outs, potentially complicating the broader SNF payment system. They might also question if existing "medically necessary" clauses already cover these treatments, making this amendment redundant or overly prescriptive.
Tradeoffs
The bill balances the need for clear, explicit coverage for a vulnerable patient population against potential concerns about increasing specificity in Medicare's payment rules, which could lead to a more fragmented or less flexible system in the long run. It also navigates the tension between ensuring access to specialized care and managing overall program costs.